Related Experiment Video
Updated: May 22, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Predicting acute and persistent neuropathy associated with oxaliplatin.
Linh M Alejandro1, Carolyn E Behrendt, Kim Chen
1Department of Pharmacy, City of Hope National Medical Center, Duarte, CA, USA. lalejandro@ucsd.edu
American Journal of Clinical Oncology
|May 2, 2012
Summary
Predicting oxaliplatin-induced peripheral neuropathy is possible using clinical factors. This can help doctors counsel patients on chemotherapy risks and management.
Area of Science:
- Oncology
- Clinical Pharmacology
- Neuroscience
Background:
- Colorectal cancer treatment often involves modified FOLFOX6 (mFOLFOX6) chemotherapy.
- Oxaliplatin, a key component of mFOLFOX6, can cause peripheral neuropathy.
- Predicting and managing this side effect is crucial for patient care.
Purpose of the Study:
- To identify predictors of oxaliplatin-associated peripheral neuropathy during mFOLFOX6 therapy.
- To develop a prognostic model for acute and persistent neuropathy.
Main Methods:
- Prospective follow-up of patients receiving mFOLFOX6 chemotherapy.
- Logistic regression to estimate per-cycle risk of acute and persistent neuropathy.
- Proportional hazards regression to predict time to persistent neuropathy.
Main Results:
- Most patients (84%) experienced neuropathy; 74% had acute and 48% had persistent symptoms.
- Risk factors for neuropathy included body surface area, prior neuropathy, and lower body weight.
- Age decreased acute neuropathy risk; cumulative oxaliplatin dose and prior persistent neuropathy increased it.
Conclusions:
- Clinical factors routinely available can predict oxaliplatin-induced neuropathy.
- A validated prognostic score for persistent neuropathy could aid in patient counseling.
